Kancera AB (publ) (KAN) - Total Assets
Based on the latest financial reports, Kancera AB (publ) (KAN) holds total assets worth Skr46.70 Million SEK (≈ $5.03 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Kancera AB (publ) debt service capacity to assess how comfortably operating cash covers total debt obligations.
Kancera AB (publ) - Total Assets Trend (2010–2024)
This chart illustrates how Kancera AB (publ)'s total assets have evolved over time, based on quarterly financial data. See KAN book value for net asset value and shareholders' equity analysis.
Kancera AB (publ) - Asset Composition Analysis
Current Asset Composition (December 2024)
Kancera AB (publ)'s total assets of Skr46.70 Million consist of 73.1% current assets and 26.9% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr46.36 Million | 69.3% |
| Accounts Receivable | Skr2.00 Million | 3.0% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr18.00 Million | 26.9% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2010–2024)
This chart illustrates how Kancera AB (publ)'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Kancera AB (publ).
Key Asset Composition Facts
- Current vs. Non-Current Assets: Kancera AB (publ)'s current assets represent 73.1% of total assets in 2024, an increase from 57.2% in 2010.
- Cash Position: Cash and equivalents constituted 69.3% of total assets in 2024, up from 46.9% in 2010.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 26.0% of total assets, a decrease from 42.0% in 2010.
- Asset Diversification: The largest asset category is cash and equivalents at 69.3% of total assets.
Kancera AB (publ) Competitors by Total Assets
Key competitors of Kancera AB (publ) based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Syndax Pharmaceuticals Inc
NASDAQ:SNDX
|
USA | $472.67 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $506.75 Million |
|
Chengdu Kanghua Biological Products
SHE:300841
|
China | CN¥3.94 Billion |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
|
China | CN¥1.84 Billion |
Kancera AB (publ) - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.02 | 6.14 | 6.54 |
| Quick Ratio | 8.02 | 6.30 | 6.54 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr25.12 Million | Skr65.00 Million | Skr60.53 Million |
Kancera AB (publ) - Advanced Valuation Insights
This section examines the relationship between Kancera AB (publ)'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.43 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | 1.9% |
| Total Assets | Skr66.91 Million |
| Market Capitalization | $1.98 Million USD |
Valuation Analysis
Below Book Valuation: The market values Kancera AB (publ)'s assets below their book value (0.03x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Kancera AB (publ)'s assets grew by 1.9% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Kancera AB (publ) (2010–2024)
The table below shows the annual total assets of Kancera AB (publ) from 2010 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Skr66.91 Million ≈ $7.20 Million |
+1.93% |
| 2023-12-31 | Skr65.64 Million ≈ $7.06 Million |
-45.63% |
| 2022-12-31 | Skr120.74 Million ≈ $12.99 Million |
-9.50% |
| 2021-12-31 | Skr133.41 Million ≈ $14.36 Million |
+60.53% |
| 2020-12-31 | Skr83.10 Million ≈ $8.94 Million |
+87.37% |
| 2019-12-31 | Skr44.35 Million ≈ $4.77 Million |
-2.59% |
| 2018-12-31 | Skr45.53 Million ≈ $4.90 Million |
-11.11% |
| 2017-12-31 | Skr51.23 Million ≈ $5.51 Million |
-29.86% |
| 2016-12-31 | Skr73.03 Million ≈ $7.86 Million |
+166.43% |
| 2015-12-31 | Skr27.41 Million ≈ $2.95 Million |
-24.74% |
| 2014-12-31 | Skr36.42 Million ≈ $3.92 Million |
+41.99% |
| 2013-12-31 | Skr25.65 Million ≈ $2.76 Million |
+37.38% |
| 2012-12-31 | Skr18.67 Million ≈ $2.01 Million |
-53.02% |
| 2011-12-31 | Skr39.74 Million ≈ $4.28 Million |
+183.60% |
| 2010-12-31 | Skr14.01 Million ≈ $1.51 Million |
-- |
About Kancera AB (publ)
Kancera AB (publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase I study in healthy subjects to document desired dose levels against cancer; and Phase IIa study for the … Read more